Summit Therapeutics plc Stock
Your prediction
Pros and Cons of Summit Therapeutics plc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Summit Therapeutics plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Summit Therapeutics plc | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -1.800% | 16.783% | 11.333% | -11.640% | -10.215% | -26.754% | -80.979% |
| Vaxart Inc. | 17.230% | 0.931% | -3.093% | -62.198% | -58.160% | -67.331% | -94.524% |
| Heidelberg Pharma AG | -0.840% | -1.240% | -17.869% | 10.648% | 0.844% | -54.215% | -65.160% |
News
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over
Why a $27 Million Buy Signals New Confidence in Weatherford Stock
Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?
On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest